Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Urie, Bridget K ^a   Russell, Duncan S ^a   Kisseberth, William C ^a   London, Cheryl A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anal sac adenocarcinoma; Apocrine gland of the anal sac; Canine; Thyroid carcinoma; Toceranib

Indexed keywords

CANIS FAMILIARIS;

INDOLE DERIVATIVE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; PYRROLE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TOCERANIB; VASCULOTROPIN RECEPTOR 2;

ANAL SAC; ANIMAL; ANIMAL DISEASE; ANUS TUMOR; ARTICLE; CARCINOMA; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PHYSIOLOGY; THYROID TUMOR;

ANAL GLAND NEOPLASMS; ANAL SACS; ANIMALS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INDOLES; MALE; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, MESSENGER; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 84872225086     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-67     Document Type: Article

References (49)

1. London C. Toceranib phosphate (Palladia) kinome 2011, Unpublished data.
2. London CA MP, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 15(11)):3856-3865.
3. London CA HA, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003, 9(7)):2755-2768.
4. Papaetis GSSK. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009, 23(6):377-389. 10.2165/11318860-000000000-00000, 19894779.
5. Gild ML BM, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011, 7:624-627.
6. Hubner RAVJ. Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2011, 11(12):1817-1827. 10.1586/era.11.171, 22117148.
7. Roskoski R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007, 356:323-328. 10.1016/j.bbrc.2007.02.156, 17367763.
8. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein M, Beaver L, Vickery K, Vail D, Hershey B, Teeinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, LaDue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S. Preliminary evidence for bioloigc activity of toceranib phosphate (Palladia®) in solid tumors. Vet Comp Oncol 2011, [Epub ahead of print].
9. Nikiforov Y. Moleular analysis of thyroid tumors. Mod Pathol 2011, 24:S34-S43.
10. Nikiforov YE LR, Biddinger PW. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88:2318-2326. 10.1210/jc.2002-021907, 12727991.
11. Gild ML BM, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011, 7(10)):617-624.
12. Legakis ISK. Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011, 2011:384213. 3095897, 21603167.
13. Adeniran AJ XA, Gandi M. Correlation between genetic alterations and mircoscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222. 10.1097/01.pas.0000176432.73455.1b, 16434896.
14. Sherman S. Targeted therapies for thyroid tumors. Mod Pathol 2011, 24:S44-S52.
15. Brown RJ NS, Durtschi DC, LeBlanc AK. Expression of PDGFR-β and Kit in canine anal sac adenocarcinoma using tissue immunohistochemistry. Vet Comp Oncol 2011, 10(1):74-79.
16. Lee JJ LC, Lui WO, Hoog A, Von Euler H. A dog pedi gree with familial medullary thyroid cancer. Int J Oncol 2006, 29:1173-1182.
17. Devilee PLI, Voesten A, Rutteman GR, Vos JH, Cornelisse CJ. The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 1994, 14(5A):2039-2046.
18. Rosol TJ CC, Danks JA, Suva LJ, Steinmeyer CL, Hayman J, Ebeling PR, Martin TJ. Identification of parathyroid hormone-related protein in canine apocrine gland adenocarinoma of the anal sac. Vet Pathol 1990, 27:89-95. 10.1177/030098589002700203, 2345942.
19. Meuten DJ CB, Capen CC, Chew DJ, Kociba GJ. Hypercalcemia associated with an adenocarcinoma derived from the apocrine glands of the anal sac. Vet Pathol 1981, 18:454-471.
20. Rosol TJ CC, Weisbrode SE, Horst RL. Humoral Hypercalcemia of malignancy in nude mouse model of a cnine adenocarcinoma derviced from apocrine glands of the anal sac. Lab Invest 1986, 54(6)):679.
21. Aguirre-Hernandez JPG, Kennedy LJ, Sargan DR. Association between anal sac gland carcinoma and dog leukocyte antigen-DQB1 in the English Cocker Spaniel. Tissue Antigens 2010, 76:476-481. 10.1111/j.1399-0039.2010.01554.x, 20727114.
22. Polton GA BM, Green LM, Scase TJ. Expression of E-cadherin in canine anal sac gland carcinoma and its association with survival. Vet Comp Oncol 2007, 5(4)):232-238.
23. Licitra LLL, Granata R, Bossi P. Multikinase inhibitors in thyroid cancer. Eur J Cancer 2010, 46(6)):1012-1018.
24. Bongarzone IVP, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with cliniopathological findings. Clin Cancer Res 1998, 4(1)):223-228.
25. Santoro MCF, Hay ID, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N. Ret oncogene activation in human thyroid neoplasms is resctricted to papillary subtype. J Clin Invest 1992, 89(5)):1517-1522. 443023, 1569189.
26. Nikiforova MNNY. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008, 8(1):83-95. 10.1586/14737159.8.1.83, 18088233.
27. Bales SR CI. Targeted therapy of differentiated and medullary thyroid cancer. J Thyroid Res 2011, 2011(102636):11.
28. Phay JESM. Targeting RET receptor tyrosine kinase activation in cancer. Molecular. Pathways 2010, 16(24):5936.
29. de Groot JW LT, Plukker JT. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endorinology Rev 2006, 5:535-560.
30. Morandi AP-MI, Isacke CM. RET in breast cancer: functional and therapeutic implications. Trends Mol Med 2011, 17(3)):149.
31. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 1998, 90(7):519-523. 10.1093/jnci/90.7.519, 9539247.
32. Ito YOY, Sato M, Sawai H, Funahashi H, Murase T, Hayakawa T, Manabe T. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 2005, 138(4)):788-794.
33. Zeng QCY, Zhu Q, Yu Z, Wu X, Huang K, Zhou M, Han S, Zhang Q. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Internal Med Res 2008, 36(4)):656-664.
34. Takaya KYT, Arai H, Tamura N, Miyamoto Y, Itoh H, Nakao K. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J Mol Med 1996, 74(10):617-621. 10.1007/s001090050065, 8912182.
35. Iwahashi NNT, Tezel G, Iwashita T, Asai N, Murakumo Y, Kiuchi K, Sakata K, Nimura Y, Takahashi M. Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma. Cancer 2002, 94(1)):167-174.
36. Ohshima YYI, Takeda K, Iida M, Kumasaka M, Matsumoto Y, Kato M. c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One 2010, 5(4):310279.
37. Kan ZJB, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466(7308)):869-873.
38. Ha HT LJ, Urba S, Koenig RJ, Giordano T, Worden FO. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010, 20(9)):975-980.
39. Keefe SM CM, Brose MA. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 2010, 16(3)):778-783.
40. Rees KA SH, Brindle NP. The receptor tyrosine kinase Tie1 is expressed and activated in epithelial tumor cell lines. Int J Oncol 2007, 31(4)):893-897.
41. Ito YYH, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A. Tie-1 tyrosine kinase expression in human thyroid neoplasms. Histopathology 2004, 44(4)):318-322.
42. Meunier-Carpentier SDJ, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C, Charpin C. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005, 26(4)):977-984.
43. Mitsutake NNH, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, Yamashita S. Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid 2002, 12(2)):95-99.
44. Artega C. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003, 284(1):122-130. 10.1016/S0014-4827(02)00104-0, 12648471.
45. Bergkvist GTYD. Epidermal growth factor receptor as a therapeutic target in veterinary oncology. Vet Comp Oncol 2011, 9(2):81-94. 10.1111/j.1476-5829.2010.00237.x, 21569194.
46. Sethi KSS, Das S, Rajput S, Mazumder A, Roy B, Patra S, Mohanty B, El-Naggar AK, Mandal M. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol 2011, 9(3)):187-199.
47. Lin TY FJ, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood 2010, 115(21)):4217-4225. 3398750, 20233974.
48. Yonemaru KSH, Murakami M, Yanai T, Masegi T. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (Flt-1, Flk-1, and Flg-1) in canine vascular tumors. Vet Pathol 2006, 43:971-980. 10.1354/vp.43-6-971, 17099154.
49. Higgins RJ DP, LeCouteur RA, Bollen AW, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN. Spontaneous canine gliomas: overexpression of EGFR, PDGR-α and IGFBP2 demostrated by tissue microarray immunophenotyping. J Neurooncology 2010, 98:49-55.